Nimotop (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels on the smooth muscle of cerebral arteries. This action reduces calcium entry into the cells, causing relaxation and preferential dilation of intracranial vessels, which counteracts vasospasm and improves cerebral perfusion after hemorrhage.

The dosing regimen for Nimotop is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Healthcare professionals adjust the intravenous infusion rate and duration according to established guidelines and individual needs.

The safety of Nimotop (nimodipine) in pregnancy or while breastfeeding has not been definitively established. Clinicians should weigh potential benefits against unknown risks and consider alternative therapies when treating pregnant or lactating patients.

To order Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimotop (nimodipine) is a dihydropyridine calcium channel blocker with higher selectivity for cerebral vessels, whereas many other agents in the class primarily affect peripheral vasculature. This brain‑selective profile makes nimodipine especially useful for preventing vasospasm after subarachnoid hemorrhage, while other blockers are often used for hypertension or angina.

Nimotop should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Nimotop is given intravenously under the supervision of qualified healthcare personnel. The infusion is typically started shortly after the subarachnoid hemorrhage event and continued for a prescribed period, with continuous monitoring of vital signs and neurological status.

The most serious adverse events include severe hypotension, bradycardia, and rare allergic reactions such as anaphylaxis. Prompt recognition and management of these conditions are essential, and patients should be monitored closely during infusion.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. Caution is also advised for individuals with uncontrolled hypotension, severe hepatic impairment, or those taking interacting medications that could cause dangerous blood‑pressure drops.